English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The chemotherapeutic agents doxorubicin (DXR) and 4'-epi-doxorubicin were separately conjugated to the human monoclonal antibody CLNIgG, which binds strongly to human malignant glioma cells. The antibody-drug conjugates were more potent than the free drugs in killing human glioma cells in vitro and in vivo (subcutaneous glioma model). A biodistribution study using [14-14C]DXR-CLNIgG conjugate indicated that immunoconjugates delivered at least five times more DXR to glioma tissues than free DXR alone in nude mice without increasing the concentration in other tissues. In a nude rat intracerebral glioma model, intracarotid hyperosmolar perfusion to achieve blood-brain barrier (BBB) opening caused a 640% increase in the DXR-CLNIgG concentration in intracerebral tumor tissue. Human monoclonal antibody-drug conjugates in combination with BBB opening is a potential new approach to the treatment of malignant gliomas.

Human Monoclonal Antibody-Drug Conjugates in the Experimental Treatment of Malignant Gliomas —Studies In Vitro and In Vivo—